TechBio Recursion will be launching a Phase I/II clinical trial of REC-1245 for the treatment of biomarker-enriched solid tumours and lymphoma, following the go-ahead from the US Food and Drug Administration (FDA). REC-1245 is a potent and selective RBM39 degrader with a potential first-in-class profile. Recursion identified the novel regulatory role of RBM39 associated with […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!